Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Ticker SymbolNAUT
Company nameNautilus Biotechnology Inc
IPO dateAug 07, 2020
CEOMr. Sujal Patel
Number of employees155
Security typeOrdinary Share
Fiscal year-endAug 07
Address2701 Eastlake Ave East
CitySEATTLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code98102
Phone12063332001
Websitehttps://www.nautilus.bio/
Ticker SymbolNAUT
IPO dateAug 07, 2020
CEOMr. Sujal Patel
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data